Welcome to the CKD and T2D: Developments in the management of DKD resource hub for events and learning materials. Here you can access a range of on-demand videos, podcasts and downloadable resources to support you in your ongoing education and development.
Throughout this website, the events and materials will focus on the role of Kerendia▼ (finerenone) in the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) in adults with type 2 diabetes. This website will be updated with additional materials on a regular basis, so do bookmark this site and revisit us. We hope you find these resources useful in your everyday clinical practice.
NICE TA877 guidance
Finerenone for treating chronic kidney disease in type 2 diabetes1
Technology appraisal guidance [TA877]
Published: 23 March 2023
Recommendation
1.1 Finerenone is recommended as an option for treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults. It is recommended only if:
In the FIDELIO-DKD phase 3 randomised, double-blind, placebo-controlled, multicentre clinical trial of 5734 adult patients with type 2 diabetes and chronic kidney disease who were randomised 1:1 to receive either oral finerenone or placebo, at baseline approximately 124 (4.4%) patients in the finerenone arm and 135 (4.8%) in the placebo arm were on SGLT2 inhibitors.2
Although recommendations for the use of an SGLT2 inhibitor in patients with chronic kidney disease and type 2 diabetes were introduced after the initiation of FIDELIO-DKD in 2015, a limited number of patients received concomitant SGLT2 inhibitor treatment during the FIDELIO-DKD trial.3
Finerenone (Kerendia®) is accepted for use within NHS Scotland.
Indication under review: for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.
In a randomised, double-blind, phase III study, the addition of finerenone to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker reduced the risk of the primary composite renal outcome comprising kidney failure, a sustained decrease in estimated glomerular filtration rate of ≥40% or death from renal causes compared with placebo.
References:
Alternatively, open your phone camera application, hold it over the QR code and tap the link that appears.
The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions. Copyright 2023 Oxbridge Solutions Ltd®. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions Ltd® receives funding from advertising but maintains editorial independence. GPnotebook stores small data files on your computer called cookies so that we can recognise you and provide you with the best service. If you do not want to receive cookies please do not use GPnotebook.
Are you a Great Britain healthcare professional?
The information is intended for Great Britain healthcare professionals only.
Please confirm below.
You are leaving GP Notebook
GP Notebook is not responsible for content hosted on third party websites.
You are leaving GP Notebook
GP Notebook is not responsible for content hosted on third party websites
You will be redirected to:
https://www.scottishmedicines.org.uk/medicines-advice/finerenone-kerendia-full-smc2486/